[1] Mohammadi M,Hedayati M. A brief review on the molecular basis of medullary thyroid carcinoma[J]. Cell J. 2017, 18(4):485-492.[2] Asimakopoulos P, Nixonl J, ShahaAR. Differentiated and medullary thyroid cancer: surgical management of cervical lymph nodes [J]. Clin Oncol(R Coll Radiol), 2017, 29(5):283-289.[3] TANG J H, GAO D P, ZOU P F. Comparison of serum PCT and CRP levels in patients infected by different pathogenic mi-croorganisms:A systematic review and meta-analysis[J]. Braz J Med Biol Res, 2018, 51(7):6783.[4] GILBERT D N. Use of plasma procalcitonin levels as an adjunct to clinical micro bio logy[J]. J Clin Microbiol, 2010, 48(7):2325-2329.[5] HAMADE B, HUANG D T. Procalcitonin: Where are we now?[J]. Crit Care Clin, 2020, 36(1):23-40.[6] Mueller C, Christ-Crain M, Muller B. What cardiologists do need to know about procalcitonin[J]. Clin Lab, 2005, 51(1/2):1-4.[7] Gendrel D, Raymond J, Assicot M, et al. Measurement of procalcitonin levels in children with bacterial or viral meningitis[J]. Clin Infect Dis, 1997, 24(6):1240-1242.[8] Chalupa P, Beran O, Herwald H, et al. Evaluation of potential biomarkers for the discrimination of bacterial and viral infections[J]. Infection, 2011, 39(5):411-417.[9] Korppi M, Remes S. Serum procalcitonin in pneumococcal pneumonia in children [J]. Eur Respir J, 2001, 17(4):623-627.[10] Eberhard OK, Haubitz M, Brunkhorst FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease(systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection[J]. Arthritis Rheum, 1997,40(7):1250-1256.[11] ALGECIRAS-SCHIMNICH A, PREISSNER C M, THEOBALD J P, et al. Procalciton: a marker for the diagnosis and follow up of patients with medullary thyroid carcinoma[J].J Clin Endocrinol Metab,2009,94(3):861-868.[12] 姚敏,张艳。降钙素原测定在甲状腺疾病中的应用 [J]. 实用临床医药杂志,2022.26(1):95-98.